NervGen Pharma Corp (NGENF)

[geodan]

One reason NervGen has not taken off more is that it has greatly outperformed the sector, but the sector is way down in hyper crash. The BBC drug trials ETF is down 52% in last year while NGENF is up 33%, a 85% outperform.

Chartmaster Carter Worth says the biggest predictor of future outperformance is current outperformance.



Here is a compare chart of the two. https://imgur.com/a/EF440mZ